Catalyst Dossier · compiled by CeliA 🧫

BridgeBio Oncology Therapeutics, Inc. (BBOT)

Pharmaceutical Preparations · market cap $606M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-01 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-01 (est.)Phase 2 · BBT-207imp 7/10
2026-08-11Earningsimp 5/10

Pipeline

Asset	Phase	Indication
acoramidis	Phase 3	Amyloidosis
Acoramidis (AG10)	Phase 3	Amyloid Cardiomyopathy, Transthyretin-Related
Encaleret	Phase 3	Autosomal Dominant Hypocalcemia (ADH)
Infigratinib is provided as a single dose of minitablets for oral administration	Phase 2	Achondroplasia
Infigratinib 0.25 mg/kg/day	Phase 3	Achondroplasia
Infigratinib 0.016 mg/kg	Phase 2	Achondroplasia
AG10	Phase 2	Amyloid Cardiomyopathy
BBT-877	Phase 2	Idiopathic Pulmonary Fibrosis
BBT-207	Phase 2	EGFR Mutant Advanced Non-Small Cell Lung Cancer

Price & technical context

3-month

-12.8%

6-month

-37.3%

12-month

-26.6%

52-wk range

$7.12–$13.73

vs 50-day MA

-4.6%

vs 200-day MA

-25.4%

Realized vol

66.6%

Max drawdown

-48.1%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for BBOT (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 9 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.